BNP Paribas Financial Markets’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-7,328
| Closed | -$1.54K | – | 4074 |
|
|
2023
Q2 | $1.54K | Hold |
7,328
| – | – | ﹤0.01% | 3740 |
|
|
2023
Q1 | $1.17K | Sell |
7,328
-1,166
| -14% | -$518 | ﹤0.01% | 3674 |
|
|
2022
Q4 | $4.71K | Buy |
8,494
+789
| +10% | +$671 | ﹤0.01% | 3667 |
|
|
2022
Q3 | $9.17K | Sell |
7,705
-9,587
| -55% | -$10.3K | ﹤0.01% | 4196 |
|
|
2022
Q2 | $10.9K | Buy |
17,292
+9,431
| +120% | +$7.24K | ﹤0.01% | 3741 |
|
|
2022
Q1 | $8.96K | Sell |
7,861
-42,917
| -85% | -$51.3K | ﹤0.01% | 3818 |
|
|
2021
Q4 | $114K | Buy |
50,778
+34,831
| +218% | +$87.4K | ﹤0.01% | 3552 |
|
|
2021
Q3 | $54.5K | Buy |
15,947
+12,576
| +373% | +$38.8K | ﹤0.01% | 3494 |
|
|
2021
Q2 | $10.1K | Buy |
+3,371
| New | +$10.7K | ﹤0.01% | 3723 |
|
|
2021
Q1 | – | Sell |
-1
| Closed | -$2 | – | 4200 |
|
|
2020
Q4 | $2 | Hold |
1
| – | – | ﹤0.01% | 4141 |
|
|
2020
Q3 | $1 | Hold |
1
| – | – | ﹤0.01% | 4204 |
|
|
2020
Q2 | $1 | Hold |
1
| – | – | ﹤0.01% | 4301 |
|
|
2020
Q1 | $1 | Hold |
1
| – | – | ﹤0.01% | 4314 |
|
|
2019
Q4 | $1 | Sell |
1
-291
| -100% | -$319 | ﹤0.01% | 4418 |
|
|
2019
Q3 | $301 | Hold |
292
| – | – | ﹤0.01% | 4437 |
|
|
2019
Q2 | $526 | Hold |
292
| – | – | ﹤0.01% | 4400 |
|
|
2019
Q1 | $549 | Hold |
292
| – | – | ﹤0.01% | 4176 |
|
|
2018
Q4 | $345 | Hold |
292
| – | – | ﹤0.01% | 4034 |
|
|
2018
Q3 | $791 | Hold |
292
| – | – | ﹤0.01% | 4327 |
|
|
2018
Q2 | $558 | Hold |
292
| – | – | ﹤0.01% | 4320 |
|
|
2018
Q1 | $613 | Hold |
292
| – | – | ﹤0.01% | 4114 |
|
|
2017
Q4 | $593 | Sell |
292
-1,463
| -83% | -$3.04K | ﹤0.01% | 4109 |
|
|
2017
Q3 | $2.33K | Sell |
1,755
-2,301
| -57% | -$2.86K | ﹤0.01% | 4050 |
|
|
2017
Q2 | $6.37K | Buy |
4,056
+4,034
| +18,336% | +$7.78K | ﹤0.01% | 4013 |
|
|
2017
Q1 | $71 | Sell |
22
-21
| -49% | -$52 | ﹤0.01% | 4020 |
|
|
2016
Q4 | $58 | Sell |
43
-3,427
| -99% | -$4.48K | ﹤0.01% | 4121 |
|
|
2016
Q3 | $5.41K | Buy |
3,470
+1,760
| +103% | +$2.7K | ﹤0.01% | 3373 |
|
|
2016
Q2 | $2.27K | Buy |
+1,710
| New | +$8K | ﹤0.01% | 3439 |
|
|
2016
Q1 | – | Sell |
-11,212
| Closed | -$88K | – | 3173 |
|
|
2015
Q4 | $88K | Buy |
11,212
+922
| +9% | +$7.94K | ﹤0.01% | 2424 |
|
|
2015
Q3 | $87K | Buy |
10,290
+6,210
| +152% | +$57.3K | ﹤0.01% | 2478 |
|
|
2015
Q2 | $44.7K | Buy |
4,080
+2,935
| +256% | +$37.7K | ﹤0.01% | 2558 |
|
|
2015
Q1 | $16K | Buy |
+1,145
| New | +$17.5K | ﹤0.01% | 2476 |
|
|
2014
Q4 | – | Sell |
-2,871
| Closed | -$38.5K | – | 3384 |
|
|
2014
Q3 | $38.5K | Buy |
2,871
+2,617
| +1,030% | +$31.2K | ﹤0.01% | 2750 |
|
|
2014
Q2 | $3.24K | Buy |
254
+195
| +331% | +$2.03K | ﹤0.01% | 2836 |
|
|
2014
Q1 | $576 | Sell |
59
-562
| -90% | -$7.54K | ﹤0.01% | 3011 |
|
|
2013
Q4 | $8.58K | Sell |
621
-12,437
| -95% | -$176K | ﹤0.01% | 2741 |
|
|
2013
Q3 | $228K | Sell |
13,058
-4,669
| -26% | -$89.4K | ﹤0.01% | 2141 |
|
|
2013
Q2 | $287K | Buy |
+17,727
| New | +$549K | ﹤0.01% | 2038 |
|
Other funds holding INFI
BNP Paribas Financial Markets's INFI Position: Q3 2023 in Review
BNP Paribas Financial Markets sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 7,328 shares — an estimated $1.54K sold.
BNP Paribas Financial Markets first reported a position in INFI in Q2 2013 and held it in 38 quarters. The position peaked at $287K in Q2 2013. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.
- BNP Paribas Financial Markets reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- BNP Paribas Financial Markets sold 7,328 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.54K.
- BNP Paribas Financial Markets first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 38 quarters.
- BNP Paribas Financial Markets's Infinity Pharmaceuticals, Inc. position peaked at $287K in Q2 2013.
- 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2023, filed 14 Nov 2023.